2012 was the year when Dr Lim became passionate about Regenerative medicine. He begins his timeless journey into a new world of Stem Cells discoveries and realised that Stem cells transplantation in general is only simple cultured cells which is not consistently effective, especially there were very limited evidence in animals with almost none in humans for anti-ageing and diseases. Dr. Michael Lim Ming Soon pioneered the 1st Allogeneic Stem Cell transplantation for the region of Asia Pacific in 2012 for Aesthetic medicine and using source from umbilical MSC and dental pulp MSC. Due to the limitations on results, he further developed his Cell Enhancement X Cad Int (CEXCI) product line treatment, that made breakthroughs in the world of anti-ageing and diseases intervention. He has done over 1000 CEXCI treatments, and he is currently the pacesetter in the region for Stem cell therapy. His experience in the field of stem cells technology has been amicable, achieving many successful cases clinically. The 1st miraculous breakthrough, was CEXCI successfully slow down and reverse significantly the ageing process of a human. Following breakthroughs, CEXCI was able to help improve more than 40 incurable diseases inclusive of complicated disease and some selected terminal cases. Dr Lim has been passionate in training and teaching as well. He has been training doctors ever since 2012 to present, in Malaysia, Singapore, Indonesia, Taiwan and China. He was also appointed as keynote speaker in 15 countries and 26 cities, presenting about Stem Cell Technology and its applications.

Dr. Dana York is a distinguished educator and researcher specializing in dentistry and laser technology. With degrees from institutions like Carol Davila University and New York University, she has contributed significantly to the field through teaching, research, and clinical practice. Dr. York's expertise extends globally, including roles as a Clinical Assistant Professor at New York University and as President of the European Medical Laser Association. Her research, focused on laser therapy and periodontal regeneration, has earned her numerous awards and recognitions, including Best Paper Awards at prestigious conferences. Beyond her professional endeavors, Dr. York is actively involved in charitable organizations and is a talented artist and pianist.

Lou has 30 years’ experience in healthcare, financial markets, and consulting. His company, Disease Management Strategy Group, Inc.developed Wellcast ROI©, a global decision support system that forecasts the ROI of wellness, behavioral, occupational health, and pharmacological interventions (www.wellcastroi.com). He also held positions as Executive Director Care Global Partners of Brazil (a large EAP in Brazil), CEO of Clinical NetwoRx, a provider of electronic medical records, VP of Global Insight (the largest economic forecasting firm in the world, where he developed expertise in calculating country-specific productivity models),a consultant with several global consulting companies, and as an international banking executive. Mr. Servizio is a graduate of the MIT (Massachusetts Institute of Technology) with a MS/MBA in Finance, and The College of the Holy Cross (BA, Mathematics). He is also a Certified Financial Advisor. He is originally from Boston, Massachusettsand now lives in Rio de Janeiro, Brazil.

Prof. Se Na Kim serves as the Chief Executive Officer of MediArk Inc., a biotechnology company she founded in 2022, pioneering advanced drug delivery technologies. Her innovative research focuses on Metal-Organic Framework (MOF)-based platforms for controlled drug release and vaccine delivery, significantly advancing healthcare applications. She earned her Ph.D. in Bioengineering from Seoul National University in 2019 and has been an Adjunct Professor at Chungbuk National University since 2023, fostering collaboration between academia and industry. Prof. Kim has filed 29 domestic patent applications, including 4 granted patents, 7 PCT applications, and 5 international filings. She has authored 68 peer-reviewed international research articles in nanotechnology, biomaterials, and drug delivery systems, establishing her as a leading figure in these fields.

Dr. Peng Ruan is an Associate Chief Physician specializing in Gastroenterology at Renmin Hospital of Wuhan University, China. With a Ph.D. in Internal Medicine from Wuhan University, he brings extensive expertise in hepatology. Dr. Ruan's diverse professional journey includes roles as a Resident Physician in General Internal Medicine and ICU, as well as leadership positions in Gastroenterology. He has also served as a Visiting Scholar at INSERM U1052, Université Claude Bernard, Lyon, France. Dr. Ruan's research focus encompasses the study of chimeric protein transcription of HBV integration sites and the detection of intrahepatic HBV cccDNA in chronic hepatitis B patients. His contributions have been supported by grants from the National Natural Science Fund of Hubei Province and the Shiyan Science Technology and Innovation Committee.

Dr. Salma Daoud earned their Ph.D. in Biochemistry in December 1997 from Université de Sherbrooke, Quebec, Canada. They began their career as a teacher of Biochemistry and Biology at the Institut Préparatoire de Biologie et Géologie in Tunis, Tunisia, before joining the Venoms and Toxins Laboratory at the Institut Pasteur de Tunis in 2003. There, they pioneered research on antimicrobial, antiviral, and antifungal peptides derived from animal venoms. Currently, Dr. Salma Daoud focuses on the biological effects of chemically synthesized decavanadates, exploring their non-toxic potential as antitumoral and antibacterial agents. With a robust academic career spanning over two decades, they have supervised numerous Master’s and Ph.D. students, delivered lectures at international scientific conferences, and published extensively in peer-reviewed journals, contributing significantly to the fields of biochemistry and therapeutic innovation.

Dr. Nemat Khansari, a Ph.D. Iranian native was awarded his D.V.M. degree from Tehran University, School of Veterinary Medicine (1970), Tehran, Iran. After six years of practice in Tehran in 1975, he immigrated to the US. Dr. Khansari earned his M.S. degree and his Ph.D. in Immunology from the University of Illinois (1981), Urbana, IL. He was then offered a postdoctoral position in the Department of Microbiology and Immunology, Medical Sciences University of South Carolina, Charleston, SD, where he published 17 articles in wellrespected journals like Sciences magazine. He also earned a clinical pathology certificate. In 1983, he became Cellular Division Director at IMREG, Inc. in New Orleans, LU. In this position, he directed research on Imreg I and Imreg II, purified endogenous immunomodulators to be applied for treating and managing HIV infection. From 1985 to 1995, he served as an assistant professor in the Department of Veterinary Medical Science at North Dakota State University, Fargo, ND. In this position, in addition to teaching immunology, he directed research in the field of aging immunology and re-juvenescence of aged mice using growth hormone and other immunomodulators. In 1990, he returned to Tehran and accepted a Deputy Director position at the Iranian Pasteur Institute, where he established the Biotechnology division. Dr. Khansari also served as Research Deputy Managing Director of the Iranian Blood Bank. From 1991 to 2009, he served as Professor and Vice Chairman of the Department of Immunology at Tehran Medical School. Dr. Khansari, from 2002 to 2006, served as an Iranian Vice President’s Biotechnology & Biosafety advisor, Chairman of the Biotechnology and Biodiversity Committee, Iranian Environmental Protection Organization, Elected member (Asia and Oceania representative) of the Compliance Committee for CBN Biosafety Protocol, and Biosafety Expert for CBD, UNEP. After retirement from Medical School in 2006, he returned to the US and became Director of the NK-Immunotherapy Laboratory in Orange County, CA, from 2013 to 2021. At the same time, Nemat served as Director of theClinical Diagnostic Laboratory of the Gandhi Hotel-Hospital in Tehran, Iran. In 2020, Nemat was elected as a member of the Board of Directors and became the Chairman of the Board of Gandhi General Hotel Hospital from 2020 to 2022. Nemat is concurrently Director of Sattarkhan Medical Laboratory in Tehran, Iran, and serves as Chief Editor of Vaccine & Vaccination Open Journal. He has published 94r esearch articles in English journals, 20 in Iranian journals, and 12 books (in Biotechnology and Immunology) in Farsi.

Ms. Julissa Soto, CEO of Latino Health Equity Consulting, is a nationally recognized leader in vaccines and immunization outreach, particularly for underserved communities. Since the COVID-19 pandemic, her innovative Cultural Validation strategy has facilitated over 30,000 vaccinations and distributed 130,000 test kits. Her contributions have earned numerous accolades, including "Julissa Soto Day" proclaimed by Colorado Governor Jared Polis and the 2023 Immunization Champion Award. A Spanish-speaking, first-generation immigrant, Julissa has hosted over 300 vaccine clinics and serves as an advisor to organizations like Vaccinate Your Family and the University of Colorado Children’s Hospital. Her two decades of experience and dedication to health equity continue to bridge critical gaps in healthcare accessibility.

Dr. Slavica Jurukovska Born on May 6, 1957, in Bitola, North Macedonia, Dr. Slavica Jurukovska is a distinguished pharmacist and expert in pharmaco informatics and pharmaceutical regulation. She earned her Master of Pharmacy in 1987 and later specialized in pharmaco informatics at the University "St. Cyril and Methodius" in Skopje, receiving her specialist degree in 2007. Certified as a key trainer educator by the World Health Organization in 2006, Dr. Jurukovska has built an extensive career spanning clinical pharmacy, academia, and regulatory management. Throughout her career, she has held key positions from pharmacist and head of pharmacy at a major medical center in Bitola to leadership roles in regulatory affairs and quality management at prominent organizations in Skopje. An active contributor to the field, she has authored over 40 research papers and serves in various capacities within national pharmaceutical associations, advancing pharmacy practice and regulatory standards in North Macedonia. Fluent in English, Serbian, and Croatian, Dr. Jurukovska continues to shape the future of pharmacy through her expertise and leadership.

Dr. Sherif Fahmy is a Professor of Pharmacy & Dean for Scientific Affair at University of Nottingham (01/2010 - Present). Dr Famy is a Cofounder Business Development at Biocity Limited (03/2009 - Present), which is the largest science incubator in the United Kingdom. Dr Famy is also founder & Chief Business Officer at AI Pharma Ltd (10/2020 - Present).Additionally, Dr sherif is a Chief Research & Development Innovation director at Pfizer (02/2013 - Present), which is a leading research-based biopharmaceutical company. Dr Famy is also a President at Association Of British Pharmaceutical Industry (04/2021 - Present), which exists to make the UK the best place in the world to research, develop and use new medicines and vaccines. A world leader in the field of AI in pharma and healthcare sectors

Dr. Bijan Almassian is the President and CEO of CaroGen Corporation (www.carogencorp.com), an emerging immunotherapy company and a spin-off from Yale School of Medicine. In this role, Dr. Bijan Almassian provides visionary leadership to execute the company’s business strategy and oversee its technical development. With extensive experience as a Senior Pharmaceutical Executive, Dr. Bijan Almassian has a proven track record of success in leading Biotechnology R&D operations, project management, and strategic alliances in both startup and mid-sized life science companies. Over the course of their career, Dr. Bijan Almassian has excelled in developing new products through various phases of research and development. Dr. Bijan Almassian’s expertise spans medicinal chemistry, including pharmacokinetics and pharmacodynamics, product development, and preclinical and clinical development. Their strategic planning skills and tactical management have been instrumental in advancing product pipelines, creating operational infrastructures to support technology development, and leading cross-functional teams to deliver innovative solutions. Prior to joining CaroGen, Dr. Bijan Almassian held several senior executive roles at Vion Pharmaceuticals (VION), a spin-off from Yale University. As Vice President of Drug Development at Vion, they established the company’s drug development operations, leading to the successful filing of INDs and the development of five drugs and biologics through all phases of research and development. Dr. Bijan Almassian has also held scientific and management positions at Genelabs and Genzyme, further enriching their background in drug discovery and development. Dr. Bijan Almassian earned a Master’s degree from Northeastern University and a Ph.D. from the Massachusetts College of Pharmacy. Following this, they conducted cancer research as an NIH Postdoctoral Fellow at Boston University Medical School. Their deep and diverse expertise in drug discovery, development, and strategic management has made them a distinguished leader in the pharmaceutical and biotechnology sectors.

Dr. Barry T. Rouse is a distinguished immunologist and veterinary scientist with a prolific career spanning over five decades. Born and educated in England, he earned his degree in Veterinary Medicine from the University of Bristol, UK, in 1965. He further pursued postgraduate studies, obtaining MSc and PhD degrees from the University of Guelph, Canada, followed by postdoctoral training at the Walter and Eliza Hall Institute of Medical Research in Melbourne, Australia (1970-1972). Dr. Rouse's academic journey led him to the University of Saskatchewan, Canada, where he served on the faculty for five years before joining the College of Veterinary Medicine at the University of Tennessee in 1977. He currently holds the esteemed positions of Lindsay Young Distinguished Professor and Institute Professor. In recognition of his contributions to the field, he was awarded the Doctor of Science (DSc) degree from the University of Bristol in 1995. As a leading expert in viral immunology and immunopathology, Dr. Rouse’s research has been extensively funded by the NIH, supporting the training of over 80 PhD students and postdoctoral researchers. He has published over 460 scientific articles, achieving a current h-index of 94. Notably, he ranks as the 8th most cited scientist in the USA affiliated with an Agriculture or Veterinary school. Dr. Rouse has received numerous awards for his groundbreaking research. While he remains actively engaged in the scientific community, his current focus includes writing reviews with former trainees in viral pathogenesis, teaching a graduate course in viral pathogenesis, and delivering invited lectures at conferences worldwide.

Dr. EL BITAR is an esteemed Associate Professor specializing in Pediatrics and Pediatric and Adolescent Gynecology. He serves as the Chairman of the Pediatrics Department at CHIREC hospital in Brussels, Belgium, while also holding a position as a University Professor. With a strong commitment to advancing public health, Dr. Bitar is recognized as an international speaker on various topics related to vaccination, including general vaccination practices and vaccine hesitancy. His expertise and dedication to educating both healthcare professionals and the public make him a valuable contributor to the ongoing dialogue on immunization.

Dr. Samuel Kofi Tchum is a Chief Biomedical Scientist and Regional Medical Laboratory Scientist (RMLS) for the Bono East Region with over 22 years of experience in public health program management, disease surveillance, laboratory diagnostics, and infectious disease modelling. His research focuses on micronutrient supplementation, malaria, and anaemia burden. Dr. Tchum holds a PhD and M.Phil. in Biochemistry from KNUST, where he also earned his bachelor's degree. He lectures at the College of Health and Wellbeing, Kintampo, and has over 20 publications in peer-reviewed journals. He serves as an Academic Editor and board member of PLOS ONE.

Mrs. Nae Young Chun is a senior researcher in the R&D department at MediArk Inc. She earned her M.S in Bioengineering from Seoul National University in 2020. Her research focuses on vaccine and drug-delivery systems based on Metal-organic frameworks (MOFs). Her work spans diverse applications of MOFs,and filed thirteen patent applications. She is the author of one peer-reviewed publication.

Nure Mozammel Kiro is a Professor and Head, Physical Medicine & Acupuncture, Gonoshasthaya Community Based Medical College Hospital & Gono University, Dhaka, Bangladesh. Dr. Nure Mozammel Kiron is a distinguished academic and practitioner with over four decades of experience in integrated and complementary medicine. Born on November 1, 1958, he holds an MD, Ph.D. in Acupuncture, and a Doctorate in Acupuncture from the Open International University for Complementary Medicine, Sri Lanka, affiliated with WHO and Beijing University of Traditional Medicine. He is a licensed practitioner with credentials from the Acupuncture Society (UK), Washington State Department of Health (USA), and Denmark, among others. As President & Executive Director of InventionBio and leader of the KNOW biotechnology consortium in Wrocław, Dr. Kiron has pioneered biotechnology solutions in biorefinery and green chemistry. His expertise spans acupuncture, physiotherapy, and medical education, with international presentations at events like the Saudi International Medical Education Conference (2010) and the World Congress for Pain Clinicians (2012). He has authored numerous publications, including books on patient care adopted in Bangladesh’s national curriculum, and serves as editor for international medical journals. Fluent in English, Japanese, Chinese, Hindi, Urdu, Arabic, and Bengali, Dr. Kiron has received international awards, including a Gold Medal from the 33rd World Congress by ALMA-ATA.

Mrs. Yu Jin Oh is a researcher in the R&D department at MediArk Inc. She earned her B.S. in Applied Chemical Engineering from Kyungpook National University in 2019. Her research focuses on drug-delivery systems based on Metal-organic frameworks(MOFs). Her work spans diverse applications of MOFs, and filed six patent applications.